



**Angiogenesis, Exudation, and Degeneration 2024
February 3, 2024**

Program Directors: Philip J. Rosenfeld, Harry W. Flynn, Jr., and Thomas A. Albini

PROGRAM

Subject to Change

Saturday, February 03, 2024

7:50 am **Welcome and Overview / Pre-Program Test**
Philip J. Rosenfeld, Harry W. Flynn, Jr., MD, and
Thomas A. Albini

Session I: OCTomics

Moderators: Philip Rosenfeld, Giovanni Gregori, and Omer Trivizki

Panelists: K. Bailey Freund, Amitha Domalpally, Srinivas Sadda, Omer Trivizki,
Alessandro Berni, David Sarraf, Yuxuan Cheng, Jie Lu, Ruikang Wang, James
Fujimoto, and Toshinori Murata

8:00 **New Imaging Findings from High-Res OCT**
K. Bailey Freund

8:10 **Trizonal Distribution of Drusen and SDD with *En Face* OCT Maps to
Photoreceptor Density**
David Sarraf

8:20 **Multimodal Assessment of OCT Biomarkers of GA and its Precursors**
Amitha Domalpally

8:30 **Precursor Lesions for Development of Atrophy in AMD**
Srinivas R. Sadda

8:40 **A Comparison Between the Grading of iRORA and cRORA on OCT B-
Scans with the Grading of Persistent Hypertransmission Defects on
En Face OCT images**
Omer Trivizki

- 8:50 **Algorithms to Detect and Quantify Drusen, Choroidal Hypertransmission Defects, and Hyperpigmentation Applicable to Both SD-OCTA and SS-OCTA Scans**
Philip J. Rosenfeld
- 9:00 **SS-OCTA Imaging of High-Risk OCT Biomarkers that Predict Disease Progression in Intermediate AMD**
Alessandro Berni
- 9:10 **Automated Segmentation and Quantification of Calcifying Drusen Applicable to Both SD-OCT and SS-OCT Scans**
Jie Lu
- 9:20 **Calcified Drusen Prevent the Detection of the Underlying Choriocapillaris using Swept-Source Optical Coherence Tomography Angiography**
Yuxuan Cheng
- 9:30 **Automated Measurement of Outer Retinal Thickness as a Biomarker for Assessing AMD Progression**
Ruikang Wang
- 9:40 **SS-OCT Angiography for Mapping Retinal Capillary Structure and Assessing Flow**
James G. Fujimoto
- 9:50 **Leakage Detection Through OCT-Angiography Using Artificial Intelligence-Inferred Fluorescein Angiography**
Toshinori Murata

Session II: Non-Exudative AMD

Moderators: Jaclyn L. Kovach, Zohar Yehoshua, and Philip J. Rosenfeld
Panelists: Christine Curcio, Carel B. Hoyng, Lawrence Yannuzzi, Giovanni Staurenghi, Emily Y. Chew, Seung-Young Yu, Giuseppe Querques, and Pearse A. Keane

- 10:00 **Early Onset AMD: Lessons to Learn**
Carel B. Hoyng
- 10:10 **Zonal Resolution of Widespread Drusen**
Lawrence A. Yannuzzi
- 10:20 **Lysolipids are Prominent in Subretinal Drusenoid Deposits**
Christine A. Curcio
- 10:30 **The Importance of Basal Lamellar Deposits in AMD**
Giovanni Staurenghi

- 10:40 **Classification and Regression Tree (CART) Analyses for Intermediate Age-Related Macular Degeneration---AREDS/AREDS2**
Emily Y. Chew
- 10:50 **Impact of Risk Factors on Progression and Vision Impairment of Geographic Atrophy in a Korean Patient Cohort**
Seung-Young Yu
- 11:00 **Predictors of GA Development in Type 3 MNV Treated with Anti-VEGF Therapy**
Giuseppe Querques
- 11:10 **Foundation Models and AMD**
Pearse A. Keane

Session III: Emerging Therapies for Non-Exudative AMD

Moderators: Ninel Z. Gregori, Philip J. Rosenfeld, and Raquel Goldhardt

Panelists: Mario Saravia, Philip J. Rosenfeld, Allen C. Ho, Carl Danzig, Jeffrey S. Heier, Peter K. Kaiser, and Eleonora Lad

- 11:20 **Balloon Angioplasty for AMD: An Update**
Mario Saravia
- 11:30 **Optogenetics for Restoring Vision in Geographic Atrophy Secondary to Advanced AMD**
Allen C. Ho
- 11:40 **AVD-104 for Geographic Atrophy: Glyco-Immunologic Modulation of Macrophage Activity**
Carl Danzig
- 11:50 **Retinal Structure Improvements with OpRegen RPE Cell Therapy in a Phase I/IIa Study in Geographic Atrophy**
Allen C. Ho
- 12:00 pm **Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy: Results of the ARCHER Study**
Jeffrey S. Heier
- 12:10 **Elamipretide Update - Entering Phase 3**
Peter K. Kaiser
- 12:20 **LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration**
Eleonora Lad

Session IV: Visual Function Testing and Complement inhibition for the Treatment of GA

Moderators: Sander R. Dubovy, Omer Trivizki, and Philip J. Rosenfeld

Panelists: Nadia K. Waheed, Michael S. Ip, Karl G. Csaky, Ursula Schmidt-Erfurth, Usha Chakravarthy, Arshad M. Khanani, David R. Lally, Justis P. Ehlers, Glenn J. Jaffe, Dilsher Dhoot, Roger A. Goldberg, and Nathan C. Steinle

- 12:30 **Comparability of Functional Retinal Testing Across Devices in AMD Patients and Normal Controls**
Nadia K. Waheed
- 12:40 **Functional Endpoints in Geographic Atrophy: An Analysis from the Chroma and Spectri Clinical Trials**
Michael S. Ip
- 12:50 **The Use of High Density Focal Photopic Microperimetry to Follow Response to Anti-Complement Therapy in Patients with Geographic Atrophy**
Karl G. Csaky
- 1:00 **AI in GA: How to Screen, Identify and Monitor Patients in the Real-World**
Ursula Schmidt-Erfurth
- 1:10 **2-year Expanded Efficacy Data from the GATHER 2 Trial**
Arshad M. Khanani
- 1:20 **Safety Findings From the GATHER Program Including 2-year Results from the GATHER2 Trial**
David R. Lally
- 1:30 **Functional Consequences of Avacincaptad Treatment in the GATHER Trials**
Usha Chakravarthy
- 1:40 **Hypertransmission Defects and Ellipsoid Zone Integrity Dynamics in the GATHER Clinical Trials**
Justis P. Ehlers
- 1:50 **Does Initial GA Growth Rate Predict GA Lesion Growth Rate and Response to Therapy at 2 years: 2-year Follow-up Data from GATHER 2**
Glenn J. Jaffe
- 2:00 **Update on Pegcetacoplan for the Treatment of Geographic Atrophy**
Dilsher Dhoot

- 2:10 **Functional Benefits with Pegcetacoplan**
Roger A. Goldberg
- 2:20 **An Anchored-Matching Adjusted Indirect Comparison of the Phase 3 Trials for GA: Pegcetacoplan vs. Avacincaptad Pegol**
Nathan C. Steinle

Session V: Real World Experience with Complement Inhibition for GA

Moderators: Thomas A. Albin, Philip J. Rosenfeld, and Janet L. Davis

Panelists: Nadia K. Waheed, Michael S. Ip, Ursula Schmidt-Erfurth, Karl G. Csaky, Usha Chakravarthy, Arshad M. Khanani, David R. Lally, Justis P. Ehlers, Glenn J. Jaffe, Mathew MacCumber, Omer Trivizki, Andre J. Witkin, Dilsher Dhoot, Roger A. Goldberg, Lawrence Singerman, Nathan C. Steinle and Charles C. Wykoff

- 2:30 **Management of Geographic Atrophy with Pegcetacoplan in Clinical Practice: First Time Data Presentation from a Large Multi-Center Study**
Mathew MacCumber
- 2:40 **Defining Occlusive Retinal Vasculitis**
Thomas A. Albin
- 2:50 **Retinal Vasculitis Following Intravitreal Pegcetacoplan: An Update from the ASRS ReST Committee**
Andre J. Witkin
- 3:00 **Panel Discussion: Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD**

Session VI: Emerging Therapies for Exudative AMD

Moderators: Luis J. Haddock, Stephen G. Schwartz, and Nicolas A. Yannuzzi

Panelists: Mark R. Barakat, Xiaodong Sun, David Eichenbaum, Arshad M. Khanani, Charles C. Wykoff, Carl D. Regillo, Nancy Holekamp, Anat Lowenstein, and David M. Brown

- 3:30 **KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study**
Mark R. Barakat
- 3:40 **Clinical Trails Evaluating LX102 Anti-VEGF Gene Therapy in Patients with Wet AMD**
Xiaodong Sun

- 3:50 **Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase 2 Pharmacodynamic Study**
David Eichenbaum
- 4:00 **First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD**
Arshad M. Khanani
- 4:10 **THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration**
Charles C. Wykoff
- 4:20 **THE DAVIO 2 TRIAL: Subgroup Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration**
Carl D. Regillo
- 4:30 **Home OCT Guided Management of Patients with nAMD**
Nancy Holekamp
- 4:40 **Longitudinal AI-based Fluid Quantification and its Implication for Remote Patient Monitoring**
Anat Loewenstein
- 4:50 **Is 12 Weeks the New Norm? What Determines Why Some Patients Need More Frequent Intravitreal Dosing?**
David M. Brown

Session VII: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: High-Dose Aflibercept

Moderators: Thomas A. Albini, Maura DiNicola, and Philip J. Rosenfeld

Panelists: W. Lloyd Clark, Gemmy Cheung Chui Ming, Diana V. Do, and John A. Wells

- 5:00 **96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study**
W. Lloyd Clark
- 5:10 **Aflibercept 8mg for PCV Subgroup in the PULSAR Study**
Gemmy Cheung Chui Ming
- 5:20 **Aflibercept 8mg for Diabetic Macular Edema: Update on the 96-Week Results of the PHOTON Study**
Diana V. Do

5:30 **Aflibercept 8 mg: Safety Outcomes from the CANDELA, PULSAR, and PHOTON Studies**
John A. Wells

5:40 **Discussion**

Session VIII: Current Anti-VEGF Therapies for Exudative AMD and Retinal Vascular Diseases: Faricimab

Moderators: Thomas A. Albini, Maura DiNicola, and Philip J. Rosenfeld

Panelists: Jennifer Lim, Rishi Singh, Ramin Tadayoni, Robyn Guymer, and Arshad M. Khanani

5:50 **Targeting Ang-2 and VEGF: Biology, Pharmacokinetics, and Latest Clinical Data in nAMD and DME**
Jennifer I. Lim

6:00 **Emerging Imaging and Biological Markers Supporting Angiopoietin-2 in nAMD and DME**
Rishi Singh

6:10 **Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies**
Ramin Tadayoni

6:20 **Voyager Study- Update on Faricimab in the Real World**
Robyn Guymer

6:30 **Insights from Clinical Practice - Review of First Year Experience with Faricimab in the Real World**
Arshad M. Khanani

6:40 **Discussion**

Session IX: Diabetic Retinopathy and Retinal Vascular Diseases

Moderators: Harry W. Flynn, Jr., Justin H. Townsend, and Basil Williams

Panelists: Jennifer K. Sun, Quan Dong Nguyen, Baruch Kuppermann, Robert Bhisitkul, David S. Boyer, Felipe Pereira, Veeral Sheth, Dante Pieramici, Peter A. Campochiaro, Darius M. Moshfeghi, and Martin Friedlander

6:50 **OCT Angiography in Diabetic Retinopathy**
Harry W. Flynn, Jr.

- 7:00 **Predictors of Diabetic Retinopathy Worsening on Ultrawide Field Imaging**
Jennifer K. Sun
- 7:10 **OCS-01 for Diabetic Macular Edema: A New Perspective on Dexamethasone**
Quan Dong Nguyen
- 7:20 **Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: Interim Results from the First In-Human Phase 2 RIPPLE-1 Trial**
Baruch Kuppermann
- 7:30 **Subgroup analysis and effect of disease severity in the BEHOLD phase 2 study of UBX1325 in DM**
Robert Bhisitkul
- 7:40 **RZ402: A Novel Orally Administered Plasma Kallikrein Inhibitor Targeting Diabetic Macular Edema**
David S. Boyer
- 7:50 **Oral 3TC for Center-Involved Diabetic Macular Edema: A Randomized Clinical Trial**
Felipe Pereira
- 8:00 **APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as the Endpoint**
Veeral Sheth
- 8:10 **The Path Forward for PDS: Technical Data Supporting Device Improvements and Septum Dislodgement Mitigation**
Dante Pieramici
- 8:20 **The Impact of Continuous Delivery of Ranibizumab with PDS on Retinal Nonperfusion in Diabetic Retinal Disease**
Peter Campochiaro
- 8:30 **Combined Analysis of BUTTERFLEYE/FIREFLEYE NEXT Aflibercept for ROP Treatment Trials and the Emerging ROP Prevention Trials**
Darius M. Moshfeghi
- 8:40 **What's New with MacTel2?**
Martin Friedlander
- 8:50 **Post-Program Test and Closing Remarks**
- 8:55 **Meeting Adjourns**